The manifestations of digestive system diseases ( nausea, vomiting, dyspepsia, abdominal pain, jaundice, and malnutrition ).
Conditions
Interventions
Liver surgery group:Domestic robot surgery was performed for liver diseases.
Biliary tract surgery group:Domestic robot surgery was performed for biliary tract diseases.
Pancreatic surgery group:Surgical treatment for pancreatic disease.
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients requiring hepatic, biliary, or pancreatic surgery who meet the corresponding indications: (1) Hepatic Group: Primary candidates include hepatocellular carcinoma with tumor diameter =5 cm or located in peripheral hepatic segments (segments S2–S6). Tumors 1 cm with potential malignancy, bile duct stones, gallbladder cancer at Stage I/II, and hilar cholangiocarcinoma (Bismuth-Corlette types I, II, selected type III, and selected type IV without portal vein or hepatic artery invasion). (3) Pancreatic Group: Resectable pancreatic cancer at Stage I or II (according to the 8th edition of the AJCC Cancer Staging Manual); benign and malignant pancreatic tumors; pancreatic neuroendocrine tumors—functional types (e.g., insulinomas, gastrinomas), and non-functional tumors defined as 6 cm, or 3 cm; cytology suggestive of malignancy), solid pseudopapillary neoplasms, and intraductal papillary mucinous neoplasms (absolute surgical indications: cytology suggestive of malignancy, presence of solid mass, jaundice, main pancreatic duct dilation >=10 mm, or enhancing mural nodule >=5 mm; relative surgical indications: cyst diameter >=40 mm, main pancreatic duct dilation 5.0–9.9 mm, serum CA19-9 >=39 U/mL, enhancing mural nodule =5 mm/year, or development of acute pancreatitis or new-onset diabetes); other benign or low-grade malignant tumors. 2. Age 18–75 years, regardless of gender; 3. Good patient compliance, capable of understanding the study procedures, willing to provide informed consent, and able to adhere to medical advice and attend scheduled follow-up visits; 4. Absence of severe systemic comorbidities.
Exclusion criteria
Exclusion criteria: 1.Have serious heart, lung, brain, liver, kidney disease, can not tolerate surgery or anesthesia; 2.Can not tolerate pneumoperitoneum; 3.severe coagulation disorder; 4.With distant metastasis of other tissues or organs, extensive metastasis in the abdominal and pelvic cavity of the tumor; 5.Have a serious uncontrolled disease or acute infection; 6.Patients with cardiovascular and cerebrovascular diseases, blood system diseases, can not meet the surgical criteria; 7.Patients with immune system diseases and can not be controlled, can not meet the surgical criteria; 8.Multiple history of abdominal surgery, severe abdominal adhesions; 9.Pregnant or lactating women; 10.The patient 's follow-up was not completed or the cause of death during the follow-up was unknown. 11.The researchers believe that it is not suitable for patients to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surgical Success Rate;Rate of complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of minimally invasive effect;Oncology efficacy evaluation;Other outcome indicators; | — |
Countries
China
Contacts
Public ContactZhang Taiping
Peking Union Medical College Hospital
Outcome results
None listed